Nicotine Science and Policy

Clinical guidance on e-cigarettes is moving from avoidance towards structured, evidence-informed advice. The SRNT recommendations recognise that adult smokers are already asking clinicians about vaping, and that many need options beyond traditional cessation tools. That shift matters because shared decision-making requires more than caution; it requires clear comparisons between continued smoking, complete switching and nicotine abstinence. Harm reduction belongs in the clinical conversation when it helps patients move away from combustion.

Nicotine’s history is far more complex than the way it is usually discussed. The same substance has been framed as poison, dependence driver, medicine and harm reduction tool, depending on dose, delivery and context. That matters because public health debates often flatten nicotine into a single moral category. Better policy starts by separating the substance from the smoke, the risk from the rhetoric, and the product from the purpose it may serve.

Australia’s tobacco excise debate shows how quickly public health policy can become an organised crime opportunity. Extremely high taxes may be designed to discourage smoking, but they can also make illegal cigarettes profitable enough to sustain violence, corruption and a market beyond normal controls. Enforcement alone cannot fix incentives this large. A credible strategy should reduce smoking while keeping consumers inside legal channels and making lower-risk nicotine alternatives easier to access than illicit tobacco.

“They don’t count” captures one of the deepest failures in nicotine policy. Smokers, vapers and users of safer nicotine products are often treated as statistics, problems or collateral damage rather than people whose choices determine whether harm is reduced in practice. A global war on nicotine can lose sight of the real target: disease and death caused by smoking. Public health should count the people it claims to protect, especially those trying to move away from combustion.

Clinicians now have stronger grounds to discuss nicotine e-cigarettes as part of smoking cessation care. The JAMA recommendations recognise that adult smokers need patient-centred advice on the full range of evidence-based options, including vaping where appropriate. That matters because misperceptions about relative risk can keep people tied to cigarettes even after repeated quit attempts. Medical guidance should be clear enough to help smokers move away from combustion, while still explaining limits, uncertainty and the need to switch completely.